The positive forecast of ‘Sivextro’ expecting sales worth of $900 billion before 2019

Published: 2014-12-01 10:47:06

Updated: 2014-12-01 10:47:06

‘Sivextro (generic name: tedizolid)’, a super antibiotic developed by Dong-A ST, is positively forecasted to make the highest sales, including sales in the U.S. and Europe, worth of at least $600 to $900 million in 2019.

KDB Daewoo Securities Co. made the forecast above through the latest analytic report of the pharmaceutical industry, and showed its supports, such as profiles of the Sivextro’...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.